透明细胞肾细胞癌基因组生物标志物的当前格局
本文系统综述了透明细胞肾细胞癌(ccRCC)基因组生物标志物的临床转化现状,涵盖体细胞突变(VHL、PBRM1、SETD2、BAP1)、拷贝数变异、转录组多基因特征及特定免疫细胞群,评估其与生存及系统治疗反应的关联。结论指出目前尚无组织或血液基生物标志物纳入常规临床实践,需进一步研究验证以改善风险分层与临床决策。
要点
- 体细胞突变(VHL、PBRM1、SETD2、BAP1)、拷贝数变异、转录组多基因特征及免疫细胞群是ccRCC候选基因组生物标志物。
- 许多标志物已评估与生存的关联,较少评估对系统治疗反应的预测价值。
- 目前尚无组织或血液基ccRCC生物标志物纳入常规临床实践。
核心结论
- 尽管尚无组织或血液基ccRCC生物标志物纳入常规临床实践,该领域仍在快速扩展,亟需开发并验证这些工具以改善肾癌患者诊疗。
研究设计与样本
- 系统性文献检索的范围综述,聚焦基于基因组的生物标志物,重点纳入评估临床结局的研究。
主要发现
- 肿瘤测序技术的进步快速增加了对ccRCC分子基础的认识,并发现了多个候选基因组生物标志物。
- 候选标志物包括体细胞基因突变如VHL、PBRM1、SETD2和BAP1,拷贝数变异,转录组多基因特征及特定免疫细胞群。
- 许多标志物已评估与生存的关联,较少标志物被评估为系统治疗反应的潜在预测因子。
临床怎么用
- 原文结论指出目前尚无组织或血液基ccRCC生物标志物纳入常规临床实践,需进一步研究验证以改善风险分层和临床决策。
局限性
- 原文指出需进一步研究以持续完善和验证这些分子工具用于风险分层。
- 原文指出在目前开发的任何生物标志物被采纳进入临床实践之前,仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Dramatic gains in our understanding of the molecular biology of clear cell renal cell carcinoma (ccRCC) have created a foundation for clinical translation to improve patient care. OBJECTIVE: To review and contextualize clinically impactful data surrounding genomic biomarkers in ccRCC. EVIDENCE ACQUISITION: A systematic literature search was conducted focusing on genomic-based biomarkers with an emphasis on studies assessing clinical outcomes. EVIDENCE SYNTHESIS: The advancement of tumor sequencing techniques has led to a rapid increase in the knowledge of the molecular underpinnings of ccRCC and with that the discovery of multiple candidate genomic biomarkers. These include somatic gene mutations such as VHL, PBRM1, SETD2, and BAP1; copy number variations; transcriptomic multigene signatures; and specific immune cell populations. Many of these biomarkers have been assessed for their association with survival and a smaller number as potential predictors of a response to systemic therapy. In this scoping review, we discuss many of these biomarkers in detail. Further studies are needed to continue to refine and validate these molecular tools for risk stratification, with the ultimate goal of improving clinical decision-making and patient outcomes. CONCLUSIONS: While no tissue or blood-based biomarkers for ccRCC have been incorporated into routine clinical practice to date, the field continues to expand rapidly. There remains a critical need to develop and validate these tools in order to improve the care for patients with kidney cancer. PATIENT SUMMARY: Genomic biomarkers have the potential to better predict outcome and select the most appropriate treatment for patients with kidney cancer; however, further research is needed before any of these currently developed biomarkers are adopted into clinical practice.
引用
- Cotta BH, Choueiri TK, Cieslik M, et al. Current Landscape of Genomic Biomarkers in Clear Cell Renal Cell Carcinoma. Eur Urol. 2023. PMID: 37085424. doi:10.1016/j.eururo.2023.04.003
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。